At less than $100/share, it makes a BUYOUT COMPELLING.
Think about it:
$1,017.00/share at PE of 10
$2,034.00/share at PE of 20
$4,068.00/share at PE of 40
Lets go into the details:
There are 10,000 patients in the US + EU at a cost of $300,000/patient/year.
That yields $3B total revenue in the market.
Take that $3B and divide it by 28.82M shares to get $104.09/share.
But wait, we have to subtract out the costs per year (total) of $68.74M which, when divided by 28.82M shares means we pull out $2.39/share to cover all costs.
So take the $104.09 (revenue) and back out $2.39 to cover all costs and that puts EPS at $101.70/share.